Lexaria Bioscience (LEXX) Share-based Compensation Growth (3y) (2018 - 2026)
Lexaria Bioscience (LEXX) Share-based Compensation Growth (3y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.91% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.35% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 17.49% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.95% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.55% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 7.39% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 30.98% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | 4.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 4.50% |
| Feb 28, 2026 | 92.34% |
| Nov 30, 2025 | 2.88% |
| Aug 31, 2025 | -19.23% |
| May 31, 2025 | 64.92% |
| Nov 30, 2024 | -37.57% |
| May 31, 2024 | -5.89% |
| Nov 30, 2023 | 141.62% |
| Aug 31, 2023 | 26.19% |
| May 31, 2023 | -50.77% |
| Feb 28, 2023 | -67.05% |
| Nov 30, 2022 | -24.91% |
| Aug 31, 2022 | 31.04% |
| May 31, 2022 | -33.40% |
| Nov 30, 2021 | 85.46% |
| May 31, 2021 | -13.79% |
| Feb 28, 2021 | -26.43% |
| Aug 31, 2020 | -113.04% |
| Feb 29, 2020 | 37.70% |
| Nov 30, 2019 | 14.64% |